Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 08, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
December 11, 2017 10:00 ET
|
Kura Oncology, Inc.
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of...
Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
December 10, 2017 09:00 ET
|
Kura Oncology, Inc.
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine...
Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017
December 06, 2017 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the company’s analyst and investor meeting to discuss imetelstat clinical data will take...
Kura Oncology to Host Investor Day on November 16, 2017
November 09, 2017 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 07, 2017 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting
November 01, 2017 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Third Quarter 2017 Financial Results
October 31, 2017 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
October 27, 2017 10:50 ET
|
Kura Oncology, Inc.
Confirmed partial responses observed in four out of six patients with HRAS mutant HNSCCTipifarnib demonstrates rapid and durable responses, with partial responses observed beyond one...
Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference
October 16, 2017 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...